Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Macdonell

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 31, 2025
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis ConsortiumChristina Kazzi, Nabil Seery, Sarah Griffith, et al.
Journal of Neuroinflammation|May 20, 2026
Plasma proteome in LGI-1 autoimmune encephalitisRobb Wesselingh, Nabil Seery, Katherine Ko, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Journal of the Neurological Sciences|October 11, 2025
Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomesKatherine Y Ko, Nabil Seery, Christina Kazzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology|September 29, 2025
Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortiumKatherine Y Ko, Christina Kazzi, Nabil Seery, et al.
Brain, Behavior, and Immunity|December 7, 2025
Biomarkers of neuroaxonal and astrocytic pathology in autoimmune encephalitisRobb Wesselingh, Sarah Griffith, Katherine Ko, et al.
Journal of Neurology|April 25, 2025
Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium studyNabil Seery, Robb Wesselingh, Paul Beech, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 31, 2025
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis ConsortiumChristina Kazzi, Nabil Seery, Sarah Griffith, et al.
Journal of Neuroinflammation|May 20, 2026
Plasma proteome in LGI-1 autoimmune encephalitisRobb Wesselingh, Nabil Seery, Katherine Ko, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Journal of the Neurological Sciences|October 11, 2025
Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomesKatherine Y Ko, Nabil Seery, Christina Kazzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology|September 29, 2025
Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortiumKatherine Y Ko, Christina Kazzi, Nabil Seery, et al.
Brain, Behavior, and Immunity|December 7, 2025
Biomarkers of neuroaxonal and astrocytic pathology in autoimmune encephalitisRobb Wesselingh, Sarah Griffith, Katherine Ko, et al.
Journal of Neurology|April 25, 2025
Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium studyNabil Seery, Robb Wesselingh, Paul Beech, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Pageof 6